Depressivität bei Patienten mit chronischer Hepatitis C vor und während der Behandlung mit α-Interferon und RibavirinJana Marit Schüle1.1232.32.1.45605#16267892.2.1011577#2091213614#57142.3.151617613#17618192.4.2.4.1.20212223242526272.4.2.282930312.4.3.32333.3.1.343536567#152373839403.2.41423.3.433.3.1.444546474849505152613#199533.3.2.54555657583.4.594.60616263645.5.1.5.1.1.65666768695.1.2.707172735.2.7475767778795.3.80816.6.1.81826.2.83847.84858687888.8.1.8.1.1.888990919293949596978.2.8.2.1.9899556#330558#314100565#3608.2.2.101102530#326103104105539#313106107501#3121088.3.8.3.1.1091101118.3.2.1121131148.4.1159.9.1.115116418#391171181191201211221231249.2.125126529#308127509#288128509#297129453#307130442#3071319.3.1321339.4.134135530#324136518#3159.5.10.13710.1.13813910.2.14010.3.14114214314414510.4.10.4.1.14614714814915015115215315410.4.2.15515610.4.3.15710.4.4.15815916016110.4.5.16216316416511.166167168169LiteraturverzeichnisAnhang 1: FallbeschreibungenAnhang 2: AbkürzungsverzeichnisAnhang 3: Die Allgemeine Depressions Skala (ADS)Anhang 4: Das Beck'sche Depressions Inventar (BDI)9#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#209#20deInhaltsverzeichnisHilfe Literaturverzeichnis Adda J (1902): L'ictère émotif, Thèse pour le Doctorat en Médecine. Thèse de Paris. Zitiert nach Leyendecker (1990) Ader R : Presidential address: Psychosomatic and psychoimmunologic research. Psychosom Med 42 ; 3 (1980) 307-21 Ader R, Cohen N (1981) : Psychoneuroimmunology.

San Diego:

Academic Press Ader R: Historical Perspectives on Psychoneuroimmunology. In Friedman H, Klein TW, Friedman AL (Hrsg.): Psychoneuroimmunology, Stress, and Infection.

New York:

CRC Press (1996) Ahmed A, Keeffe EB: Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference. J Gastroenterol Hepatol 14 Suppl (1999) S12-8 Alexander L (1950): Psychosomatic medicine. Deutsch: Psychosomatische Medizin.

Berlin-New York:

De Gruyter Alter MJ, Mast EE: The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am .23; 3 (1994) 437-55 Arzneimittelkommission der deutschen Ärzteschaft (1997): Arzneiverordnungen: Ratschläge für Ärzte und Studenten.

Köln:

Deutscher Ärzte-Verlag Ballieux RE: The Mind and the Immune System. Theor Med 15; 4 (1994) 387-95 Bartholomew U, Klapp BF, Leyendecker B, Scheer JW: Depressivität und Selbstwertgefühl bei Patienten mit akuter Virushepatitis. Psychother Psychosom Med Psychol 41; 9-10 (1991) 354-61 Bartrop RW, Lazarus L, Luckhurst E, Kiloh L: Depressed lymphocyte function after bereavement. Lancet 16; 1 (1977) 834-6 Besedovsky HO, Sorkin E: Network of immune-neuroendocrine interactions. Clin Exp Imm 27 (1977) 1-12 Bluthé RM, Crestani F, Keeleym KW, Dantzer R: Mechanisms of the behavioral effects of interleukin 1. Annals of the New York Academy of Sciences 650 (1992) 268-274 Bodenheimer HC Jr., Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB: Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 26; 2 (1997) 473-7 Bonkovsky HL, Woolley JM: Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 29; 1 (1999) 264-70 Botez MI, Dinu R, Nanulescu M: Troubles neuropsychiques et données morpgo-pathologiques dans l'hépatite aigue infectieuse. Acta Neurol Psychiatr hellen 5 (1966) 1-14, zitiert nach Leyendecker (1990) Bowlby J: Effects on behaviour of disruption of an affectional bond. Eugen Soc Symp 4 (1968) 94-108 Bresci G, Parisi G, Banti S, Capzia A: Re-treatment of interferon-resistant patients with chronic hepatitis C with interferon-alpha. J Viral Hepat 2; 3 (1995) 155-8 Brillanti S, Foli M, Di Tomaso M, Gramantieri L, Masei C, Bolondi L: Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Ital J Gastroenterol Hepatol 31; 2 (1999) 130-4 Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Miglioli M, Masci C, Barbara L: A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107; 3 (1994) 812-7 Brouwer JT, Hansen BE, Niesters HGM, Schalm SW: Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 30; 2 (1999) 192-8 Bunney WE Jr, Davis JM: Norepinephrine in depressive reactions. A review. Arch Gen Psychiatry 13; 6 (1965) 483-94 Caliezi JM: Die Hepatitis, eine Ausweichkrankheit bei bewußter Verzweiflung suizidaler Tiefe? (Depressionsersatz). Schweiz Rundschau Med 61 (1980) 1620-8 Canonico PG, Kende M, Huggins JW: The toxicology and pharmacology of ribavirin in experimental animals. In Smith RA, Knight V, Smith JAD (Hrsg.): Clinical application of ribavirin.

Orlando:

Academic Press (1984) Caporaso N, Romano M, Marmo R, DeSio I, Morisco F, Minerva S, Coltori M: Hepatitis C infection is an additive risk factor for development of hepatocellular carcinoma in patients with cirrhosis. J Hepatol 12; 3 (1991) 367-71 Capuron L, Ravaud A: Prediction of the Depressive Effects of Interferon Alfa Therapy by the Patient’s Initial Affective State. N Eng J Med 340; 17 (1999) 1370 Caravati CM: Posthepatitis Syndrome. Southern Medical Journal 37 (1944) 251-7 Choo QL, Weiner AJ, Overby LR, Kuo G, Houghton M, Bradley DW: Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis. British Med Bulletin 46; 2 (1990) 423-41 Cohen JJ: Individual Variability and Immunity. Brain, Behaviour, and Immunity 13; 2 (1999) 76-9 Conjeevaram HS: Etiology of Hepatitis C: A Reassessment. Am J Gastroent 94; 5 (1999) 1135-6 Cooke RG, Warsh JJ, Hassey GM, McLaughlin BJ et al.: Epstein-Barr virus antibodies and severity of depression. Biol Psychiatry 29 (1991) 621-3 Coppen AJ, Doogan DP: Serotonin and its place in the pathogenesis of depression. J Clin Psychiatry 49 Suppl (1988) 4-11 Córdoba J, Camps J, Esteban JI: The Clinical Picture of Acute and Chronic Hepatitis C. In Reesink HW ( ed ): Hepatitis C Virus. Curr Stud Hematol Blood Transf.

Basel:

Karger (1994) Cornberg M, Wedemeyer H, Manns MP: Hepatitis C: therapeutic perspectives. Forum (Genova) 11; 2 (2001) 154-62 Dalakas MC, Mock V, Hawkins MJ: Fatigue: Definition, Mechanisms, and Paradigms for Study. Semin Oncol 25; 1 Suppl 1 (1998) 48-53 Debove M: Forme tardive de l'ictère émotif. Gazette hebdomadaire de Médecine et de Chirurgie. 33, 48 (1901) 385-7, zitiert nach Leyendecker (1990) DiBisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ: Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 14; 6 (1991) 969-74 DiBisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH: A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16; 3 (1992) 649-54 DiBisceglie AM, Hoofnagle JH, Krawczynski K: Changes in hepatitis C virus antigen in liver with antiviral therapy. Gastroenterology 105; 3 (1993) 858-62 DiBisceglie AM, Bacon BR, Kleiner DE, Hoofnagle JH: Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 21; 6 (1994) 1109-12 DiBisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Hoofnagle JH: Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123; 12 (1995) 897-903 Dietrich DE, Schedlowski M, Bode L, Ludwig H, Emrich HM: A viro-psycho-immunological disease-model of a subtype affective disorder. Pharmacopsychiatry 31; 3 (1998) 77-82 Dooley JS, Davis GL, Peters M, Waggoner JG, Goodman Z, Hoofnagle HJ: Pilot study of recombinant human alpha-interferon for chronic type B hepatitis. Gastroenterology 90; 1 (1986) 150-7 Dries V, von Both I, Müller M, Gerken G, Schirmacher P, Odenthal M, Bartenschlager R, Drebber U, Meyer zum Büschenfelde K-H, Dienes HP: Detection of Hepatitis C Virus in Paraffin-Embedded Liver Biopsies of Patients Negative for Viral RNA in Serum. Hepatology 29; 1 (1999) 223-9 Dunbar HF, Wolfe TP, Rioch JM: Psychiatric aspects of medical problems: the psychic component of the disease process (including convalescence) in cardiac, diabetic and fracture patients. Amer J Psychiatr 93 (1936) 649-79 Dunn AJ: Psychoneuroimmunology, Stress and Infection. In Friedman H, Klein TW, Friedman AL (Hrsg.): Psychoneuroimmunology, Stress, and Infection.

New York:

CRC Press (1996) Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P, Weiland O: Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 25; 5 (1996) 591-8 Dusheiko G: Side Effects of Alpha Interferon in Chronic Hepatitis C. Hepatology 26; 3 Suppl 1 (1997) 112S-121S Dusheiko GM: Hepatocellular carcinoma associated with chronic viral hepatitis. Aetiology, diagnosis and treatment. British Med Bulletin 46; 2 (1990) 492-511 Dusheiko GM: Virology and sequence variation of hepatitis C: clinical significance. In Soni P, Dusheiko GM, Harrison TJ, Dhillon AP: Genetic diversity of hepatitis C virus: implications for pathogenesis, treatment, and prevention. Grand round. Lancet 345; 8949 (1995) 562-6 Eaton WW, Kessler LG: Rates of symptoms of depression in a national sample. Am J Epidemiol 114; 4 (1981) 528-38 Efendiev EM: Neuropsychische Störungen bei der Hepatitis epidemica. Terap Arch Moskva 8 (1956) 71. Zitiert bei Kipshagen (1975) Fattovich G, Giustina G, Favarato S, Ruol A: A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 24; 1 (1996) 38-47 Felten DL, Felten SY, Bellinger DL, Carlson SL, Ackerman KD, Madden KS, Olschowski JA, Livnat S: Noradrenergic sympathetic neural interactions with the immune system: Structure and function. Immunological Reviews 100 (1987) 225-60 Fichter MM, Narrow WE, Roper MT, Rehm J, Elton M, Rae DS, Lcoke BZ, Regier DA: Prevalence of mental illness in Germany and the United States. Comparison of the Upper Bavarian Study and the Epidemiologic Catchment Area Program. J Nerv Ment Dis 184; 10 (1996) 598-606 Fong TL, Fried MW, Clarke-Platt J: A Pilot Study of Rimantadine for Patients With Chronic Hepatitis C Unresponsive to Interferon Therapy. Am J Gastroenterol 94; 4 (1999) 990-3 Foster GR, Goldin RD, Thomas HC: Chronic Hepatitis C Virus Infection Causes a Significant Reduction in Quality of Life in the Absence of Cirrhosis. Hepatology 27; 1 (1998) 209-12 Frerichs FT (1858): Klinik der Leberkrankheiten. Band 2.

Braunschweig.

(zitiert nach Bartholomew 1991) Freud S (1938): Die Ichspaltung im Abwehrvorgang. In: Gesammelte Werke (1950) Band 17,

London:

Imago Frey W, Tonietti F: Der Einfluß der vegetativen Nerven auf die Milz und die Lymphocyten des Blutes. Zeitschrift für die gesamte Experimentelle Medizin 44 (1925) 597-608 Fried MW, Hoofnagle JH: Therapy of hepatitis C. Semin Liver Dis 15; 1 (1995) 82-91 Friedberg E: Über den Einfluß des vegetativen Nervensystems auf das weiße Blutbild. Monatszeitschrift für Kinderheilkunde 18 (1920) 432-42 Gale M Jr, Kwieciszewski B, Dossett M, Nakao H, Katze MG: Antiapoptotic and Oncogenic Potentials of Hepatitis C Virus Are Linked to Interferon Resistance by Viral Repression of the PKR Protein Kinase. J Virol 73; 8 (1999) 6506-16 Gidaly M, Gorgan V, Iepureanu A, Sirbu A, Schuster N: Neuro-Psychische Erscheinungen bei der Hepatitis infectiosa. Z Ges Inn Medizin 19 (1964) 519-22 Green MD, Locke SE: The immune system and its control: a possible model in herpes virus infections. J Clin Psychopharmacol 8; 1 (1988) 68-9 Groddeck G (1932): Das Buch vom Es. Psychoanalytische Briefe an eine Freundin.

Frankfurt, Berlin:

Ullstein Gulley LR, Nemeroff CB: The neurobiological basis of mixed depression-anxiety status. J Clin Psychiatry 54 Suppl (1993) 16-9 Häfner H, Freyberger H: Ikterus als psychosomatisches Krankheitsbild. Z Psychother Med Psychol 5 (1955) 107-18 Hatiegan J: Untersuchungen über die Adrenalinwirkung auf die weißen Blutzellen. Wiener Klin Wochenschrift 30 (1917) 1541-1547 Hautzinger M, Bailer M (1993): ADS, Allgemeine Depressions Skala.

Weinheim:

Beltz Test GmbH Hautzinger M: Das Beck-Depressionsinventar (BDI) in der Klinik. Nervenarzt 62; 11 (1991) 689-96 Herold G (1995): Innere Medizin. Eine vorlesungsorientierte Darstellung.

Köln:

Gerd Herold Hoofnagle HJ, Davis GL, Pappas SC, Hanson RG, Peters M, Avigan MI, Waggoner JG, Jones EA, Seeff JB: A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial. Ann Intern Med 104; 1 (1986a) 12-7 Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, DiBisceglie A, Peters M, Waggoner JG, Park Y, Jones EA: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha-interferon. A preliminary report. N Engl J Med 315; 25 (1986b) 1575-8 Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, DiBisceglie AM: Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat 3; 5 (1996) 247-52 Hoofnagle JH: Hepatitis C: The Clinical Spectrum of Disease. Hepatology 26; 3 Suppl 1 (1997) 15S-20S Hopf U, Moller B, Kuther D, Stemerowicz R, Lobeck H, Ludtke-Handjery A, Walter E, Blum HE, Roggendorf M, Deinhardt F: Long-term follow-up of posttransfusion and sporadic chronic hepatitis nonA, nonB and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 10; 1 (1990) 69-76 Huebschmann H: Über den Bedeutungsgehalt von Eßstörungen bei inneren Erkrankungen (Tuberkulose und Hepatitis). In: Meyer JE, Feldmann H (Hrsg.): Anorexia nervosa Symposium Sonderdruck.

Stuttgart

(1965) S.142-6 Inglot AD, Leszek J, Piasecki E, Sypula A: Interferon responses in schizophrenia and major depressive disorders. Biol Psychiatry 35; 7 (1994) 464-73 Irwin M, Caldwell C, Smith TL, Brown S, Schuckit MA, Gillin C: Major Depressive Disorder, Alcoholism, and Reduced Natural Killer Cell Cytotoxicity. Arch Gen Psychiatry 47 (1990) 713-9 Janssen HL, Brouwer JT, van der Mast RC, Schalm SW: Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 21; 2 (1994) 241-3 Johnson EM: Developmental toxicity and safety evaluations of ribavirin. Pediatr Infect Dis J 9; 9 Suppl (1990) S85-7 Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y: A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 105; 2 (1993) 507-12 Kalk H, Wildhirt E: Die posthepatische Hyperbilirubinämie. Z Klin Med 153 (1955) 354-87 Kanai K, Kako M, Okamoto H: HCV genotypes in chronic hepatitis C and response to interferon. Lancet 339; 8808 (1992) 1543 Kasl SV, Evans AS, Niedermann JC: Psychosocial risk factors in the development of infectious mononucleosis. Psychosom Med 41; 6 (1979) 445-66 Kayser FH: Erreger viraler Infektionskrankheiten. In Kayser FH, Bienz KA, Eckert J, Lindenmann J: Medizinische Mikrobiologie.

Stuttgart, New York:

Georg Thieme Verlag (1989) Kemeny ME, Laudenslager ML: Beyond Stress: The Role of Individual Difference Factors in Psychoneuroimmunology. Brain, Behaviour, and Immunity 13; 2 (1999) 73-5 Kennedy S: Herpes Virus Infection and Psychoneuroimmunology. In Friedman H, Klein TW, Friedman AL (Hrsg.): Psychoneuroimmunology, Stress, and Infection.

New York:

CRC Press (1996) Kiecolt-Glaser JK, Ricker D, George J, Messick G, Speicher CE, Garner, W, Glaser R: Urinary Cortisol Levels, Cellular Immunocompetency, and Loneliness in Psychiatric Inpatients. Psychosom Med 46; 1 (1984) 15-23 Kipshagen H (1975): Psychische Veränderungen bei der akuten Virushepatitis in einer Verlaufsstudie mit dem MMPI-Saarbrücken-Persönlichkeitstest. Dissertationsschrift

München

Kiyosawa K, Furuta S: Hepatitis C Virus and Hepatocellular Carcinoma. In Reesink HW ( ed ): Hepatitis C Virus. Curr Stud Hematol Blood Transf.

Basel:

Karger (1994) Klosterhalfen W, Klosterhalfen S: Psychoimmunologie. In Adler RH, Herrmann JM, Köhle K, Schonecke OW, Uexküll T.v., Wesiak W (Hrsg.): Psychosomatische Medizin (5. Neubearbeitete und erweiterte Aufl.)

München-Wien-Baltimore:

Urban&Schwarzenberg (1996) Koff RS: Impaired Health-Related Quality of Life in Chronic Hepatitis C: The How, but Not the Why. Hepatology 29; 1 (1999) 277-9 Koh, KB: Emotion and Immunity. Review. J Psychosom Res 45; 2 (1998) 107-15 Kronfol Z, Silva J, Greden J, Dembinski S, Gardner R, Carroll B: Impaired Lymphocyte Function in Depressive Illness. Life Sciences 33 (1983) 241-7 Kugler J, Schedlowski M, Schulz, KH (Hrsg.): Psychoneuroimmunology. How the brain and the immune system communicate with each other.

Lengerich:

Pabst Science Publishers (1995) Kuschinsky G, Lüllmann H, Mohr K (Hrsg.): Kurzes Lehrbuch der Pharmakologie und Toxikologie.

Stuttgart:

Thieme Verlag (1993) Lapin IP, Oxenkrug GF: Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1; 7586 (1969) 132-6 Leibowitz S, Gorman WF: Neuropsychiatric complications of viral hepatits. N Engl J Med 246 (1952) 932-7 Leyendecker B (1990): Das klinische Bild der Virushepatitis. Beschwerden, Befunde und Stimmungen im Zusammenhang mit dem Krankheitsverlauf. Dissertationsschrift

Giessen

Liang TJ: Combination Therapy for Hepatitis C Infection. Editorial. N Engl J Med 339; 21 (1998) 1549-50 Licinio J, Kling MA, Hauser P: Cytokines and Brain Function: Relevance to Interferon- α -Induced Mood and Cognitive Changes. Semin Oncol 25; 1 Suppl 1 (1998) 30-8 Linn BS, Linn MW: Anxiety and immune responsiveness. Psychol Research 49; 3 (1981) 969-70 Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285; 5424 (1999) 110-3 Lyketsos CG, Hoover DR, Guccione M, Senterfitt W, Dew MA, Wesch J, VanRaden MJ, Treisman GJ, Morgenstern H: Depressive Symptoms as Predictors of Medical Outcomes in HIV Infection. JAMA 270; 21 (1993) 2563-7 Maes M, Scharpé S, Van Grootel L, Uyttenbroeck W, Cooreman W, Cosyns P, Suy E: Higher α 1-antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: Further evidence for the existence of an inflammatory response during that illness. J Affect Disord 24; 3 (1992) 183-192 Maes M, Scharpé S, Meltzer HY, Bosmans E, Suy E, Calabrese J, Cosnys P: Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 49; 1 (1993) 11-27 Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 34; 4 (1995a) 301-9 Maes M, Smith R, Scharpe S: The monocyte-T-lymphozyte hypothesis of major depression. Psychoneuroendocrinol 20; 2 (1995b) 111-6 Magyar I (1961): Erkrankungen der Leber und der Gallenwege Band 1. Akademie-Verlag,

Berlin/DDR

Mahaney K, Tedeschi V, Maertens G, DiBisceglie AM, Vergalla J, Hoofnagle JH, Sallie R: Genotypic analysis of hepatitis C virus in american patients. Hepatology 20; 6 (1994) 1405-11 Maier KP (1995): Hepatitis –Hepatitisfolgen. Praxis der Diagnostik, Therapie und Prophylaxe akuter und chronischer Lebererkrankungen.

Stuttgart:

Thieme Mani N (1965): Die historischen Grundlagen der Leberforschung Teil I: Die Vorstellungen über Anatomie, Physiologie und Pathologie der Leber in der Antike.

Basel:.

Schwabe & Co. Mani N (1967): Die historischen Grundlagen der Leberforschung Teil II: Die Geschichte der Leberforschung von Galen bis Claude Bernard.

Basel:

Schwabe & Co. Manns MP, Cornberg M, Wedemeyer H: Current and future treatment of hepatitis C. Indian J Gastroenterol 20 Suppl 1 (2001) C47-51 Martini GA: Erkrankungen der Leber und Gallenwege. In: Gross R, Schölmerich P (Hrsg.): Lehrbuch der inneren Medizin. Schattauer,

Stuttgart

(1982) 693-753 McHutchinson JG, Poynard T: Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 19 Suppl 1 (1999) 57-65 McHutchinson, J: Hepatitis C advances in antiviral therapy: What is accepted treatment now? J Gastroent Hepat 17 (2002) 431-41 Meyer zum Büschenfelde KH, Hütteroth TH: Lebererkrankungen. In Siegenthaler W, Kaufmann W, Hornbostel H, Waller HD (ed): Lehrbuch der inneren Medizin.

Stuttgart, New York

: Georg Thieme Verlag (1992) Miller AH, Spencer, RL: Immune System and Central Nervous System Interactions. In: Kaplan HI, Sadock BJ (Hrsg.): Comprehensive Textbook of Psychiatry.

Baltimore:

Williams & Wilkins (1995) S.112-27 Miller GE, Cohen S, Rabin BS, Skoner DP, Doyle WJ: Personality and Tonic Cardiovascular, Neuroendocrine, and Immune Parameters. Brain, Behaviour, and Immunity 13; 2 (1999) 109-23 Mitscherlich A (1980): Ein Leben für die Psychoanalyse.

Frankfurt:

Suhrkamp Morgagni (1682-1771) 1990 (siehe dort) Müller N, Ackenheil M: Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 22; 1 (1998) 1-33 Newman TB: Combination Therapy for Hepatitis C Infection. N Eng J Med 340; 15 (1999) 1207 Ning Q, Brown D, Parodo J, Cattral M, Fung L, Liu M, Rotstein O et al.: Ribavirin inhibits viral induced macrophage production of TNF, IL-1, the procoagulant fg12 prothrombinase and preserves Th1 cytokine production, but inhibits Th2 cytokine response. J Immunol 160; 7 (1998) 3487-93 Nishiguchi S, Kuroki T, Nakatani S et al.: Randomized trial of the effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346; 8982 (1995) 1051-5 O'Connor NT: Interferon beta and suicide in multiple sclerosis. Lancet 347; 9012 (1996) 1417-8 Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishoji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K: Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25; 3 (1996) 283-91 Osler W (1909): Lehrbuch der Internen Medizin.

Berlin:

Urban & Schwarzenberg Otsubo T, Miyaoka H, Kamijima K, Onuki M, Ishii M, Mitamura K: Depression during interferon therpay in chronic hepatitis C patients – a prospective study. Seishin Shinkeigaku Zasshi 99; 3 (1997) 101-27 [ nur abstract: Artikel auf Japanisch ] Paar GH, Schaefer A, Drexler W: Über das Mitwirken psychosozialer Faktoren bei Ausbruch und Verlauf der akuten Virushepatitis – Bericht über eine Pilotstudie. Psychother Psychosom Med Psychol 37; 1 (1987) 23-30 Pappas SC, Hoofnagle HJ, Young N, Straus SE, Jones EA: Treatment of chronic non-A, non-B hepatitis with acyclovir: pilot study. J Med Virol 15; 1 (1985) 1-9 Papper S, Handy J: Observations in a "Control" Group of Patients in Psychosomatic Investigation. New Engl J Med 255 (1956) 1067-71 Pares A , Caballeria J, Bruguera M, Torres M, Rodes J: Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 2; 1 (1986) 33-42 Patek AJ, Daland GA: The effect of adrenalin injection on the blood of patients with and without spleens. Am J Med Sci 190 (1935) 14-22 Pavuluri MN, Smith M, Luk SL: A neuroimmune hypothesis for the aetiopathology of viral illness and manic depression: a case report of an adolescent. J Affect Disord 39; 1 (1996) 7-11 Potain M: De l'ictère émotif. La semaine médicale.

Paris

(1894) S.381-2, zitiert nach Leyendecker (1990) Potain M: De l'ictère spasmodique secondaire. Gazette des Hôpitaux.

Paris

(1879) S.834-7, zitiert nach Leyendecker (1990) Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM: A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 332; 22 (1995) 1457-62 Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24; 4 (1996) 778-89 Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 352; 9138 (1998) 1426-32 Preston H, Wright T: Interferon therapy for hepatitis C. Lancet 348; 9033 (1996) 973-4 Purcell R: The Hepatitis C Virus: Overview. Hepatology 26; 3 Suppl 1 (1997) 11S-14S Ramesh R, Munshi A, Panda SK: Prevalence of hepatitis C virus antibodies in chronic liver disease and hepatocellular carcinoma. J Gastroenterol Hepatol 7; 4 (1992) 393-5 Reichard O, Andersson J, Schvarcz R, Weiland O: Ribavirin treatment for chronic hepatitis C. Lancet 337; 8749 (1991) 1058-61 Reichard O, Norkrans G, Frydén A, Braconier J, Sönnerborg A, Weiland O: Randomised, double-blind, placebo-controlled trial of interferon α -2b with and without ribavirin for chronic hepatitis C. Lancet 351; 9096 (1998) 83-7 Reichlin S: Neuroendocrine-immune interactions. N Eng J Med 329; 17 (1993) 1246-53 Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, Rustgi V, Jones EA: Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 147; 9 (1987) 1577-80 Resch K, Szamel M: Beeinflussung des Immunsystems. In Fülgraff G, Palm D (Hrsg.): Pharmakotherpie. Klinische Pharmakologie (9. neubearb.Auflage)

Stuttgart:

G.Fischer Verlag (1995) Roberts RE, Lewinsohn PM, Seeley JR: Screening for adolescent depression: a comparison of depression scales. J Am Acad Child Adolesc Psychiatry 30; 1 (1991) 58-66 Robertson BM: The psychoanalytic theory of depression. Part I – The major contributors. Can Psychiatr Assoc J 24 ,4 (1979) 341-352 Rodger AJ, Jolley D, Thompson , Lanigan A, Crofts N: The impacts of diagnosis of hepatitis C virus on quality of life. Hepatology 30; 5 (1999) 1299-1301 Rose MS (1994): Die akute Virushepatitis im biopsychosozialen Kontext: Emotionale und immunologische Parameter im Krankheitsverlauf.

Gießen:

Verlag der Ferber’schen Universitätsbuchhandlung Rose MS, Scholler G, Klapp BF: Biopsychologische Zusamenhänge und Prädiktoren des Krankheitsverlaufs bei der akuten Virushepatitis. Psychother Psychosom Med Psychol 47 (1997) 435-445 Rose MS, Scholler G, Jorres A, Danzer G, Klapp BF: Patients’ expressions of complaints as a predictor of the course of acute hepatitis A. J Psychosom Res 48; 2 (2000) 107-13 Sadock BJ, Sadock VA (Hrsg.): Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 6.Auflage .

New York:

Lippincott Williams and Wilkins (1995) Sanchez-Tapias JM, Rodes J: Interferon in chronic hepatitis C. Lancet 346 Suppl (1995) S11 Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A: Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 26; 5 (1997) 961-6 Schedlowski M, Schmidt RE: Streß und Immunsystem. Naturwissenschaften 83; 5 (1996) 214-20 Schildkraut JJ: The catecholamine hypothesis of affective disorders. A review of supporting evidence. Int J Psychiatry 4; 3 (1967) 203-17 Schleifer SJ, Keller SE, Meyerson AT, Raskin MJ, Davis KL, Stein M: Lymphocyte function in major depressive disorder. Arch Gen Psychiatry 41; 5 (1984) 484-6 Schleifer SJ, Keller SE, Siris SG, Davis KL, Stein M: Depression and Immunity. Arch Gen Psychiatry 42; 2 (1985) 129-33 Schlesinger M, Yodfat Y: Psychoneuroimmunology, Stress and Disease. In Friedman H, Klein TW, Friedman AL (Hrsg.): Psychoneuroimmunology, Stress, and Infection.

New York:

CRC Press (1996) Schoeneich P: Zur Psychogenese der Leber- und Gallenkrankheiten. Med Klin (1952) 864-7 Schulz KH, Ferstl R: Psychoimmunologische Forschung in der Bundesrepublik Deutschland 1987. In: Florin I, Hahlweg K, Haag G, Brack UB, Fahrner EM (Hrsg.): Perspektive Verhaltensmedizin.

Berlin:

Springer (1989) Schur K (1955): Zur Metapsychologie der Somatisierung. In: Brede C (1980): Psychosomatische Medizin (zitiert nach Bartholomew 1991) Schvarcz R, Ando Y, Sonnerborg A, Weiland O: Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 23 Suppl 2 (1995) 17-21 Seeff LB: Natural History of Hepatitis C. Hepatology 26; 3 Suppl 1 (1997) 21S-28S Selye H: The evolution of the stress concept. Amer Scientist 61 (1973) 692-9 Seyfarth C (1930): Strümpell-Seyfarth Lehrbuch der speziellen Pathologie und Therapie Innerer Krankheiten. Band I.

Leipzig:

F.C.W.Vogel Sherlock S: The Post-Hepatitis Syndrome. Lancet II 482-4 Siegenthaler W, Kaufmann W, Hornbostel H, Waller HD (Hrsg.): Lehrbuch der inneren Medizin Thieme

Stuttgart:

1992. (1946) Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M, Wiktorowicz K: Indicators of immune activation in major depression. Psychiatric Research 64; 3 (1996) 161-7 Smith EM, Blalock JE: Humane lymphocyte production of corticotropin and endorphin-like substances: Association with leukocyte interferon. Proc Nat Acad Sci USA 78; 12 (1981) 7530-4 Smith RS: The macrophage theory of depression. Med Hypotheses 35 (1991) 298-306 Solomon GF, Moos RH: Emotions, immunity and disease: A speculative theoretical integration. Arch Gen Psychiat 11; 657 (1964) Song C, Lin A, Bonaccorso S, Heide C, Verkerk R, Kenis G, Bosmans E, Scharpe S, Whelan A, Cosyns P, de Jongh R, Maes M: The inflammatory response system and the availability of plasma tryptophan in patients with sleep disorders and major depression. J Affect Disord 49; 3 (1998) 211-9 Song J, Fujii M, Wang F, Itoh M, Hotta H: The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon. J Gen Virol 80 (1999) 879-86 Sternberg E: Emotions and disease: From balance of humors to balance of molecules. Nature Medicine 3; 3 (1997) 264-7 Stokes JF, Owen JR, Holmes EG: Neurological Complications of Infective Hepatitis. Brit Med J 2 (1945) 642-4 Theodor E, Regev A: Disappointing response of chronic C hepatitis to interferon. Harefuah 132; 6 (1997) 402-3 [nur abstract: Artikel auf Hebräisch] Tong MJ, el-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332; 22 (1995) 1463-6 Uexküll T.v. (1963): Grundfragen der psychosomatischen Medizin.

Hamburg:

Rowohlt Taschenbuch Verlag Uexküll T.v., Wesiak W (1996): Wissenschaftstheorie: ein bio-psycho-soziales Modell. In Adler RH, Herrmann JM, Köhle K, Schonecke OW, Uexküll T.v., Wesiak W (Hrsg.): Psychosomatische Medizin (5. Neubearbeitete und erweiterte Aufl.)

München-Wien-Baltimore:

Urban&Schwarzenberg Umber F: Erkrankungen der Leber, der Gallenwege und des Pankreas. In: Bergmann G et al.: Erkrankungen der Verdauungsorgane – Handbuch der Inneren Medizin. Band III, Teil 2.

Berlin:

Springer (1926) Ur E, White PD, Grossman A: Hypothesis: Cytokines May be Activated to Cause Depressive Illness and Chronic Fatigue Syndrome. Eur Arch Psychiatry Clin Neurosci 241; 5 (1992) 317-22 Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P: Mood and Cognitive Side Effects of Interferon- α Therapy. Semin Oncol 25; 1 Suppl 1 (1998) 39-47 Van der Poel CL, Cuypers HAT, Reesink, HW: Hepatitis C virus six years on. Review article. Lancet 344; 8935 (1994) 1475-9 von Eiff AW, Kloska G, Quint H (1967): Essentielle Hypertonie. Klinik, Psychophysiologie und Psychopathologie.

Stuttgart:

Thieme von Weizsäcker V (1951): Fälle und Probleme.

Stuttgart:

Enke von Wietersheim J, Overbeck A, Kiel K, Kohler T, Jantschek G, Feiereis H: The significance of recurrence-inducing events for patients with chronic inflammatory bowel disease. Results of a prospective longitudinal study over three years. Psychother Psychosom Med Psychol 44; 2 (1994) 58-64 von Wietersheim J, Scheib P, Keller W, Osborn W, Pritsch M, Balck F, Fritzsche K, Dilg R, Schmelz-Schumacher E: The effects of psychotherapy on Crohn's disease patients- results of a randomized multicenter study. Psychother Psychosom Med Psychol 51; 1 (2001) 2-9 Weigent DA, Blalock JE: Neuroendocrine Peptide Hormones and Receptors in the Immune Response and Infectious Diseases. In Friedman H, Klein TW, Friedman AL (Hrsg.): Psychoneuroimmunology, Stress, and Infection.

New York:

CRC Press (1996) Weiss P: Zur Frage des Emotionsicterus. Berliner Klinische Wochenschrift (1905) 102-5 Weissmann MM, Leaf PJ, Holzer CE 3rd, Myers JK, Tischler GL: The epidemiology of depression. An update on sex differences in rates. J AffectDisord 7; 3-4 (1984) 179-88 Wittkower E: Über affektiv-somatische Veränderungen. II. Mitteilung. Die Affektleukocytose. Klin Wochenzeitschrift 8 (1929) 1082 Wong ML, Bongiorno PB, Rettori V, et al.: Interleukin (IL) 1beta, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: Pathophysiological implications. Proc Natl Acad Sci USA 94 (1997) 227-32 Yoshioka K, Kakumu S, Wakita T et al.: Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 16; 2 (1992) 293-9 Younossi ZM, Perrillo RP: The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Semin Liver Dis 19 Suppl 1 (1999) 95-102 Yu MC, Tong MJ, Cousaget P, Ross RK, Govindalajan S, Henderson BE: Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United states. J Nat Cancer Inst 82; 12 (1990) 1038-41 Zorn F (1977): Mars.

München:

Fischer Zorrilla EP, McKay JR, Luborsky L, Schmidt K: Relation of stressors and depressive symptoms to clinical progression of viral illness. Am J Psychiatry 153; 5 (1996) 626-35